Ursodeoxycholic acid treatment in primary sclerosing cholangitis

James H. Tabibian; Keith Lindor

doi:10.1007/978-3-319-40908-5_11

Ursodeoxycholic acid treatment in primary sclerosing cholangitis

James H. Tabibian
, Keith Lindor

Research output: Chapter in Book/Report/Conference proceeding › Chapter

3 Scopus citations

Abstract

Primary sclerosing cholangitis (PSC) is a chronic, idiopathic liver disease which, despite extensive laboratory-based investigation, translational studies, and clinical trials, lacks established medical treatment. In this chapter, we provide a succinct, comprehensive review of research regarding the potential role for ursodeoxycholic acid as a pharmacotherapy for PSC.

Original language	English (US)
Title of host publication	Primary Sclerosing Cholangitis
Subtitle of host publication	Current Understanding, Management, and Future Developments
Publisher	Springer International Publishing
Pages	145-152
Number of pages	8
ISBN (Electronic)	9783319409085
ISBN (Print)	9783319409061
DOIs	https://doi.org/10.1007/978-3-319-40908-5_11
State	Published - Jan 1 2016

Keywords

Algorithm
Bile acids
Biliary tract diseases
Cholestasis
Cholestatic liver disease
Medical management
Outcomes
Pharmacotherapy
Pruritus
Quality of life

ASJC Scopus subject areas

General Medicine

Access to Document

10.1007/978-3-319-40908-5_11

Cite this

@inbook{74b7eb9300f8480c8cb7d0e54bccbf26,

title = "Ursodeoxycholic acid treatment in primary sclerosing cholangitis",

abstract = "Primary sclerosing cholangitis (PSC) is a chronic, idiopathic liver disease which, despite extensive laboratory-based investigation, translational studies, and clinical trials, lacks established medical treatment. In this chapter, we provide a succinct, comprehensive review of research regarding the potential role for ursodeoxycholic acid as a pharmacotherapy for PSC.",

keywords = "Algorithm, Bile acids, Biliary tract diseases, Cholestasis, Cholestatic liver disease, Medical management, Outcomes, Pharmacotherapy, Pruritus, Quality of life",

author = "Tabibian, \{James H.\} and Keith Lindor",

year = "2016",

month = jan,

day = "1",

doi = "10.1007/978-3-319-40908-5\_11",

language = "English (US)",

isbn = "9783319409061",

pages = "145--152",

booktitle = "Primary Sclerosing Cholangitis",

publisher = "Springer International Publishing",

}

TY - CHAP

T1 - Ursodeoxycholic acid treatment in primary sclerosing cholangitis

AU - Tabibian, James H.

AU - Lindor, Keith

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Primary sclerosing cholangitis (PSC) is a chronic, idiopathic liver disease which, despite extensive laboratory-based investigation, translational studies, and clinical trials, lacks established medical treatment. In this chapter, we provide a succinct, comprehensive review of research regarding the potential role for ursodeoxycholic acid as a pharmacotherapy for PSC.

AB - Primary sclerosing cholangitis (PSC) is a chronic, idiopathic liver disease which, despite extensive laboratory-based investigation, translational studies, and clinical trials, lacks established medical treatment. In this chapter, we provide a succinct, comprehensive review of research regarding the potential role for ursodeoxycholic acid as a pharmacotherapy for PSC.

KW - Algorithm

KW - Bile acids

KW - Biliary tract diseases

KW - Cholestasis

KW - Cholestatic liver disease

KW - Medical management

KW - Outcomes

KW - Pharmacotherapy

KW - Pruritus

KW - Quality of life

UR - https://www.scopus.com/pages/publications/85018869721

UR - https://www.scopus.com/pages/publications/85018869721#tab=citedBy

U2 - 10.1007/978-3-319-40908-5_11

DO - 10.1007/978-3-319-40908-5_11

M3 - Chapter

SN - 9783319409061

SP - 145

EP - 152

BT - Primary Sclerosing Cholangitis

PB - Springer International Publishing

ER -

Ursodeoxycholic acid treatment in primary sclerosing cholangitis

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this